Abstract. At the invasive front of colorectal carcinoma (CRC), the existence of tumor budding (TB), the detachment and migration of small clusters of tumor cells from the neoplastic epithelium, correlates with high incidence of local invasion and distant metastasis; however, the molecular background of TB is still unknown. In human CRC-derived SW480 cells, CD133 + cells showed cancer stem cell (CSC)-like properties, high tumorigenicity and pluripotency. By a comparative study of gene expression between CD133
Introduction
Tumor budding (TB) initially termed as sprouting, is a morphologic phenomenon observed at the advancing edge of neoplasms and is characterized by isolated or small clusters of tumor cells that detach from the neoplastic epithelium and migrate a short distance into the neoplastic stroma, which may explain the more aggressive behavior of the tumors which show this feature (1, 2) . In human colorectal carcinoma (CRC), evaluation of TB is therefore a useful prognostic marker (3, 4) , however, the detailed molecular mechanisms of TB formation remain unknown.
Recently, accumulating evidence has demonstrated that CRC consists of a heterogeneous population of cells and contains a subset of cells that initiate and propagate tumors with high efficiency (5) . Since these cells, called cancer stem cells (CSC) or cancer-initiating cells, exhibit not only stem cell properties such as self-renewal and multipotency but also resistance to chemotherapy or radiotherapy (6) , there is an urgent need to elucidate the molecular background underlying the maintenance of colorectal CSCs. Numerous colorectal CSC markers have been identified, including Lgr5 (7, 8) , CD44 (9, 10) , aldehyde dehydrogenase (ADH) (11) and, most recently, CD133 (12) . Indeed, lineagetracing studies have shown that CD133 + cells are located at the base of crypts in the intestine and generate the entire intestinal epithelium, suggesting that CD133 + cells are intestinal stem cells and susceptible to transformation into tumors that retain a fraction of mutant CD133 + CSCs (13) . CD133 + colorectal CSCs grew exponentially for more than one year in vitro as undifferentiated tumor spheres in serum-free medium, maintaining the ability to engraft and reproduce the same morphological and antigenic pattern of the original tumor (14) . A clinicopathological study on CRC reported that patients with high CD133 + CSCs had significantly poorer overall survival (15, 16) .
As described above, TB at the invasive front and CD133 + CSCs within the tumor have been established as prognostic markers of human CRC, respectively; nevertheless, the association between TB and CSCs is still unknown. In this study, we investigated the nature of colorectal CSCs and attempted to reproduce TB in vitro and in vivo to examine whether cells making up tumor buds might have CSC-like properties, or CSCs at the invasive front might form tumor buds.
Materials and methods
Cell culture, magnetic bead separation and gene transfection. Human CRC-derived SW480 cells obtained from American Type Culture Collection (Manassas, VA, USA) were maintained in RPMI-1640 (Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS; Nichirei, Tokyo, Japan) and antibiotics. For magnetic bead separation, SW480 cells were labeled with anti-CD133 microbeads (Miltenyi, Auburn, CA, USA) and separated on an autoMACS separator (Miltenyi). The human SNAI1-coding region (NM_005985) was subcloned into the pCX4bsr vector to generate pSNAI1 as described previously (17) . Using effectene transfection reagent (Qiagen, Hilden, Germany), pSNAI1 and empty vector (EV) were transduced into CD133 -SW480 cells according to the manufacturer's instruction.
Tumor sphere formation and flow cytometry. Cells were maintained in DMEM/F12 (BD Biosciences, Franklin Lakes, NJ, USA) supplemented with 20 ng/ml of epidermal growth factor (EGF; Sigma, St. Louis, MO, USA), 40 ng/ml of basic fibroblast growth factor (bFGF; Sigma) and 2 ng/ml of transforming growth factor-β1 (TGF-β1; Sigma). Tumor spheres were obtained by mixing the cells and Matrigel (BD Biosciences)-containing DMEM/F12 (Invitrogen) and plated on a 4-well chamber slide for more than four weeks. For flow cytometric analysis, cells were washed with phosphate-buffered saline (PBS) and supplemented with anti-human CD133 antibody conjugated with R-phycoerythrin (Miltenyi). The cell pellets were washed with 1% bovine serum albumin (BSA) in PBS and fixed using 1% paraformaldehyde. Expression of CD133 was analyzed using a FACS Calibur cytometer (BD Biosciences).
RT-PCR and quantitative real-time RT-PCR.
The primer sets used in this study are listed in Table Ι. RT-PCR was performed with a One-Step RT-PCR assay kit (Qiagen). Thirty minutes after incubation at 50˚C, each 25 µl reaction mixture containing 10 ng of total RNA was amplified for 30 cycles with the following regimen: denaturation at 94˚C for 30 sec; annealing at 58˚C for 30 sec and extension at 72˚C for 1 min. The products underwent electrophoresis on 2% agarose gel. Quantitative real-time RT-PCR was conducted with an ABI PRISM 7700 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) and QuantiTect SYBR Green RT-PCR kit (Qiagen). The real-time cycler conditions were reverse transcription at 50˚C for 30 min, followed by 45 cycles of denaturation at 94˚C for 15 sec, annealing at 52˚C for 30 sec and elongation at 72˚C for 30 sec. The threshold cycle (C t ) was standardized to the sample glyceraldehyde-3-phosphate dehydrogenase (GAPDH) value (∆C t = Gene C t -GAPDH C t ), and this value was then compared between two kinds of cells using the ∆∆C t method, which was then used to determine the fold change (= 2^[-∆∆C t ]).
Immunofluorescence. Cells and tumor spheres were fixed with 4% paraformaldehyde and then incubated with blocking solution containing 1% BSA. Formalin-fixed and paraffin-embedded tissue sections were also used. The antibodies used are as follows: CD133 (Miltenyi), TGF-β type 1 (TGFBR1; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and type 3 receptors (TGFBR3; Abcam, Cambridge, MA, USA), MUC2 (Santa Cruz Biotechnology), villin (Thermo Scientific, Walthan, MA, USA), MUC5Ac (Santa Cruz Biotechnology), Chromogranin A (CgA; Dako, Glostrup, Denmark), Snail (SNAI1; Abcam), E-cadherin (CDH1; BD Biosciences), vimentin (VIM; Epitomics, Burlingame, CA, USA) and α-smooth muscle actin (SMA; Abcam). Cy2-or Cy3-conjugated antibody against rabbit/mouse IgGs (GE Healthcare, Little Chalfont, UK) were used as secondary antibodies. The nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI).
Tumorigenicity test. Cells (1x10 3 -10 6 cells/200 µl Matrigel) were inoculated subcutaneously into the back of 12-week-old severe combined immunodeficiency (SCID) mice (Japan Clea, Tokyo, Japan). Four weeks after inoculation, the mice were sacrificed and paraffin-embedded tumor sections were used for hematoxylin and eosin (H&E) staining and immunohistochemistry (IHC). Initiating cell frequency was calculated using the extreme limiting dilution analysis (ELDA) (18) .
cDNA microarray analysis. Total cellular RNA was extracted using RNeasy Mini Kit (Qiagen) according to the manufacturer's recommendations from CD133 + and CD133 -SW480 cells that were sorted based on their expression for CD133 using autoMACS separator (Miltenyi). The concentration of RNA was determined by measuring the absorbance at 260 nm in a spectrophotometer. A cDNA microarray was performed by Human Expression Array version 2.0 (Agilent Technologies, Palo Alto, CA, USA). The in vitro transcription, oligonucleotide array hybridization and scanning were performed according to Takara Bio protocols (Takara Bio, Otsu, Japan). Briefly, doublestranded cDNA was synthesized from total RNA, and was labeled with RNA Fluorescence Labeling Core Kit (Takara Bio). Arrays were then scanned with GeneArray scanner (Agilent Technologies) to obtain image and signal intensities. After data normalization, significance analysis of microarray (SAM) plot analysis was performed and significantly altered genes were identified in accordance to the manufacturer's protocol (http:// chem.agilent.com).
Wound healing assay and invasion assay. For the wound healing assay, cultured cells at almost 100% confluence were serum-starved for 12 h. After scratching the monolayer, cells were washed with PBS and then cultured for 24 h. The distance of scratching in 0 h minus in 24 h was measured. Cell invasion activities were estimated using cell culture inserts with an 8-µm pore size membrane coated with Matrigel. Aliquots of 2.5x10 5 cells were placed in upper chamber with serum-free medium, whereas the lower chamber was loaded with RPMI-1640 containing 10% FBS. After 48-h incubation, the non-invading cells were removed, and the invaded cells on the lower surface of the membrane were counted.
Tissue samples and IHC.
A total of 59 formalin-fixed and paraffin-embedded stage II CRC samples obtained from Kobe University Hospital (Kobe, Japan) were collected. At the time of surgical resection, these cases were diagnosed as stage II CRC; however, metachronous lymph node metastasis was detected in 32 cases of the patients. Informed consent was obtained from all patients and the study was approved by the Kobe University Institutional Review Committee. Statistical analysis was performed using StatView 5.0.1. (SAS, Cary, NC, USA). TB was determined according to the criteria of Ueno et al (2) . IHC was performed using the labeled streptavidin-biotin kit (Dako) with antibodies against CDX2 (Biogenex, San Ramon, CA, USA) and SNAI1 (Abcam).
Results

CD133 recognizes colorectal CSCs. CD133
+ cells at the colon crypts are tissue stem cells that differentiate into enterocytes, enteroendocrine cells and goblet cells (7) . In CRC-derived SW480 cells, the frequency of CD133 + cells was only 0.18% (Fig. 1A) ; however, there were discrepancies in the expressions of the other colorectal CSC markers CD44 and Lgr5 (Fig. 1B) . Similar results were detected in the other human CRC cell lines (data not shown). We also examined the differential expressions of colon markers (CDX2, MUC2 and CD10) and epithelialmesenchymal transition (EMT) markers (CDH1, VIM and SNAI1) between CD133 + and CD133 -SW480 cells. Interestingly, CD133 + SW480 expressed extremely low levels of CDX2 and CDH1, whereas they expressed higher levels of VIM and SNAI1 (Fig. 1B) . These findings suggested that CD133 + SW480 cells were characterized by dedifferentiation and EMT.
In addition, CD133 + SW480 cells demonstrated high potential as CSCs: the tumorigenicity of CD133 + SW480 cells was 86 times higher than that of CD133 -SW480 cells (Fig. 1C and D) . The xenografts developed in SCID mice showed pluripotency by expressing the enterocyte makers MUC2 (colon), villin (small intestine), MUC5Ac (stomach) as well as the entero endocrine marker CgA (Fig. 1E) . Since CDX2 is a transcription factor that regulates development and differentiation of the intestinal epithelium (19), we transduced CDX2-expression vector (pCDX2) into CD133 + SW480 cells as a colorectal CSC differentiation model. Induction of CDX2 not only promoted cell differentiation and branch formation in three-dimensional culture but also effectively decreased tumorigenicity (unpu blished data). Thus, we concluded that CD133 recognizes colorectal CSCs.
TGF-β restores CD133
+ SW480 cells and induces EMT. To identify genes that are responsible for the maintenance of CSC-like properties, a comparative study of gene expression profiles was performed using CD133 + and CD133 -SW480 cells (Table II) . Among the down-regulated genes (>1.6-fold) in CD133 -SW480 cells, we focused on the type 1 (TGFBR1) and type 3 (TGFBR3) TGF-β receptor genes. We confirmed that expressions of TGFBR1 and TGFBR3 in CD133 + SW480 cells were higher than those in CD133 -cells at the mRNA and protein levels ( Fig. 2A and B) . Based on these results, we hypothesized that CSCs may have high sensitivity to TGF-β. TGF-β and its family members have been implicated in the development and maintenance of stem cells (20) and the induction of EMT (21) . Then, we treated CD133 + SW480 cells with TGF-β1 and found that TGF-β1 maintained the population of CD133 + SW480 cells more than in the absence of TGF-β1 (Fig. 2C) . In the culturing dish, only 6% of cells endogenously expressed SNAI1; however, when treated with TGF-β1, 59% of SW480 cells showed positive immunoreactivity against SNAI1 with loss of CDH1 expression at the cell-cell borders (Fig. 2D ) with increased levels of VIM expression (Fig. 2E) . Moreover, the induction of TGF-β-mediated EMT was confirmed by the finding the SNAI1-positive cells only at the tumor sphere surface (Fig. 2F) . Similar results were detected in the experiments using a colorectal CSC differentiation model (unpublished data). Comparative studies of gene expressions of TGF-β receptors and TGF-β-induced EMT in CD133 + and CD133 -cells were also examined in the other human CRC cell lines; however, we could not find any significant differences as was detected in SW480 cells (data not shown).
SNAI1 mediates the re-acquisition of CSC-like properties in vitro and in vivo.
Restoration of SNAI1-expression in CD133 -SW480 cells was performed to investigate the impact of EMT on the restoration of CSC-like properties. In SW480 cells, an increased population of CD133 + cells was detected when pSNAI1 was transduced into CD133 -SW480 cells (Fig. 3A) . The change in the mRNA levels of CDH1 was significant between CD133
--EV and CD133 --pSNAI1 cells; however, there was no significant change in the mRNA levels of VIM, CDX2 and MUC2 (Fig. 3B) .
Restoration of the stemness was supported by the results of a limiting dilution assay, in which frequency of development of subcutaneous tumors was significantly higher in CD133
--pSNAI1 cells than in the tumors derived from CD133 --EV cells (Fig. 3C) . In addition, transduction of pSNAI1 effectively increased the activities of cell motility, invasion and up-regulated the MMP2 levels ( Fig. 3D-F) . In the mouse xenografts derived from CD133 --pSNAI1 cells, the cancer cells showed infiltration into the stroma and formed TB-like structures with a high frequency of CD133 + cells (Fig. 3G) . Furthermore, CD133
--pSNAI1 cells showed high TGFBR1 expression and the stromal cells demonstrated SMA expression (Fig. 3G) . These findings suggest that transduction of SNAI1 strongly enhances not only the restoration of CSC properties but also the formation of tumor buds.
Induction of SNAI1 at the invasive front correlates with formation of tumor buds and metachronous lymph node metastasis.
The obtained data suggested that the mediation by TGF-β and subsequent induction of SNAI1 in CRC cells were necessary for the maintenance of the restoration of CSC-like properties. Therefore, we examined the association of SNAI1 expression and TB formation at the invasive front of 59 cases of stage II CRC. Interestingly, the incidence of TB at the invasive front in CRC cases with metachronous lymph node metastasis was higher than that in those without metachronous lymph node metastasis ( Fig. 4A and B) . Supporting this, CDX2-positive CRC cells were detected not only in the carcinoma-derived gland structures but also in the budding areas; however, SNAI1-positive CRC cells were detected only in the budding areas but not in the main tumor (Fig. 4A) . These findings suggest the possibility that TB formation at the invasive front is associated with SNAI1-mediated EMT.
Discussion
According to the CSC hypothesis, tumors possess a hierarchical organization of cells, among which a subpopulation of stem-like cells is responsible for sustaining tumor growth --EV and CD133 --pSNAI1 cells. The nuclei were stained with DAPI. (22, 23) . In this study, we analyzed the nature of colorectal CSCs to elucidate the relation with TB formation. In SW480 cells, CD133 + cells demonstrated high tumorigenicity and pluripotency, whereas CD133 + cells did not express the other CSC markers CD44 and Lgr5 in CRC-derived cell lines. In addition, various populations of CD133 + cells were detected in CRC-derived cell lines (0.1-22.54%). Nevertheless, in a colorectal CSC differentiation model, transduction of pCDX2 into CD133 + SW480 cells effectively decreased CD133 levels and tumorigenic potential. CD133 is a 115-120 kDa five-transmembrane domain glycoprotein that was originally identified as a novel protein specifically localizing in microvilli of the apical surface of mouse neuroepithelial cells (24) , and the cytoplasmic domain of CD133 can be phosphorylated by Src-family tyrosine kinases (25) . Although the biological functions of CD133 are not well understood, the association with the TGF-β signaling pathway and high tumor-forming capability of CD133 + SW480 cells strongly support the idea that this glycoprotein would be useful as a molecular target for the diagnosis and treatment of CRC. Thus, we concluded that CD133 is available for the identification of CSCs in SW480 cells.
In this study, we found that CD133 + SW480 cells expressed high levels of SNAI1, TGFBR1 and TGFBR3 transcripts. Interestingly, we found that treatment with TGF-β1 up-regulated SNAI1 expression in SW480 cells with the induction of EMT. Of note, the increase in SNAI1 expression was not distributed homogeneously, but the number of SNAI1 + SW480 cells was significantly increased in Petri dishes and in tumor spheres in Matrigel. Taken together with the fact that TGF-β1 restored CD133 + SW480 cells, these findings suggested that induction of SNAI1 by TGF-β may be closely related with restoration and maintenance of CSC properties (26) . Supporting this idea, transduction of pCDX2 into CD133 + SW480 cells effectively suppressed TGFBR1 and TGFBR3 expression but treatment with TGF-β restored CD133 + SW480 cells and induced EMT. TGF-β did not necessarily induce EMT in the other CRC-derived cell lines, which is probably associated with expression levels of TGFBR1 and TGFBR3. Moreover, transduction of pSNAI1 into CD133 -SW480 cells effectively up-regulated CD133 + cells with high tumorigenic potential in the mouse xenograft model and simultaneously increased cell motility/invasiveness and MMP2 expression. Activation of the SMAD signaling by TGF-β directly induces the expression of SNAI1, which subsequently suppresses CHD1 expression by direct binding to the E2-box sequence of the CDH1 promoter (27) . The evidence indicates that TGF-β-mediated maintenance of CSC-like properties may overlap EMT. Based on this body of evidence, we are currently attempting to identify novel molecular markers that are capable of identifying colorectal CSCs.
Finally, we considered that the restoration of stemness could be induced by the surrounding microenvironment in CRC tissues: i.e., TGF-β-induced EMT at the invasive front of CRC is closely correlated with the morphological alteration of tumor cells known as 'TB'. A previous study on patients with pT1 CRC showed that TGF-β-positive cells were observed in 91.7% of patients with presence of TB at the front of invasion, and there was a statistically significant correlation between the presence of lymph node metastasis and the positive expression of TGF-β (28). Furthermore, it has been reported that CD133 expression in colorectal carcinoma is an independent prognostic marker that correlates with low rate of survival (29) . In our findings, SNAI1 expression was significantly correlated with TB formation at the invasive front and the incidence of metachronous lymph node metastasis. Consequently, we therefore conclude that TGF-β dissolved in the CRC microenvironment may participate in the SNAI1-induced EMT and restoration of CSC-like properties, which may cause metachronous metastasis in patients with stage II CRC (Fig. 4C) . Detection of TB at the invasive front of CRC must be generalized for the accurate evaluation of prognosis of patients with CRC.
